The table below shows NEKTAR THERAPEUTICS's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
-
-
-
-
-
-
Cost of revenue
-
$0.00
$0.00
$0.00
$4.43M
$9.74M
Gross profit
-
-
-
-
-
-
R&D
$35.68M
$27.25M
$29.89M
$30.48M
$35.03M
$29.72M
SG&A
NKTR annual revenue (10-K history)
NEKTAR THERAPEUTICS reported annual revenue of $55.23M for fiscal year 2025. That is down 43.9% from $98.43M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $165.44M (FY 2016) to $55.23M. Figures come from the company's audited annual reports as filed with the SEC.
